Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275792 | 0.83 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL2724166 | 0.81 | MEN1 (0.40) | CNR1CNR2MEN1HTTKMT2A | |
| SCHEMBL31377070 | 0.81 | ALDH1A1 (0.43) | MEN1HTTKMT2A | |
| SCHEMBL1506544 | 0.81 | ALDH1A1 (0.43) | MEN1HTTKMT2A | |
| SCHEMBL20790210 | 0.79 | ALDH1A1 (0.47) | CNR1CNR2MEN1HTTKMT2A | |
| SCHEMBL531737 | 0.76 | L3MBTL1 (0.47) | MEN1HTTKMT2A | |
| SCHEMBL30760989 | 0.76 | L3MBTL1 (0.47) | MEN1HTTKMT2A | |
| SCHEMBL2005026 | 0.75 | CNR1 (0.39) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL28022375 | 0.73 | PKM (0.55) | CNR1CNR2HTT | |
| SCHEMBL6437850 | 0.72 | CYP19A1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1973546-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | MERCK SHARP & DOHME LLC | 2009-01-15 | — | — | US | disclosed |
| EP-1973546-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CNR1 1198/4885CNR2 1722/4885MEN1 3533/4885 |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | CETP, APOB, MTTP | CNR1 1909/4885CNR2 3189/4885MEN1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.